Incytevs.Vertex Pharmaceuticals
INCY vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 5.6× larger than Incyte by market cap; Incyte trades at the lower P/E (14.2 vs 29.0); year to date, Incyte leads (+14.2% vs +11.0%).
Side by side
| INCY | VRTX | |
|---|---|---|
| Market cap | $22.9B | $128B |
| Price | $112.79 | $510.08 |
| Today | +0.0% | +1.4% |
| Return YTD | +14.2% | +11.0% |
| Return 1Y | +32.1% | +19.5% |
| Since June 26, 2026 | −0.8% | +3.8% |
| P/E | 14.2 | 29.0 |
| P/S | 3.9 | 10.1 |
| P/B | 3.6 | 6.3 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More INCY & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.